Prelude Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Prelude Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,000	Closed	-$120K	–	1752
2018 Q1	$120K	Buy	+8,000	New	+$122K	0.01%	822
2017 Q4	–	Sell	-8,500	Closed	-$128K	–	1460
2017 Q3	$128K	Buy	+8,500	New	+$112K	0.01%	798
2016 Q4	–	Sell	-1,800	Closed	-$13K	–	1625
2016 Q3	$13K	Buy	+1,800	New	+$12.2K	﹤0.01%	1400
2016 Q1	–	Sell	-5,000	Closed	-$49K	–	1341
2015 Q4	$49K	Buy	+5,000	New	+$45.1K	0.01%	1050

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Prelude Capital Management's FOLD Position: Q2 2026 in Review

Prelude Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 639,885 shares — an estimated $9.25M sold.

Prelude Capital Management first reported a position in FOLD in Q3 2014 and held it in 25 quarters. The position peaked at $9.25M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Prelude Capital Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 639,885 Amicus Therapeutics shares in Q2 2026, an estimated $9.25M.
Prelude Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 25 quarters.
Prelude Capital Management's Amicus Therapeutics position peaked at $9.25M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.